跳至主要内容
临床试验/DRKS00003203
DRKS00003203招募中不适用

on-interventional study on the safety and efficacy of an Abraxane(R) mono therapy for the therapy of patients with metasasized breast cancer with special consideration of the toxicity profiles - Abraham study

OnkoDataMed GmbH !0 个研究点目标入组 450 人开始时间: 2011年7月26日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
450

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 99 Years(—)
性别
Female

入选标准

  • Secured metastasized breast cancer with at least 1 metastasis (by means of RECIST or diffuse metastasis of the skeloton)
  • Gender: female
  • Alge: =18 ýears
  • Signed patient informed consent
  • Therapy in a practice which is member of the BNGO
  • Adequate general condition = 2 on the ECOG Scale
  • Adequate bone marrow reserves: number of neutrophiles < 1,5 x 1E9 /L before start of the therapy

排除标准

  • Pregnancy and lactation
  • Lack of compliance

研究者

发起方
OnkoDataMed GmbH !

相似试验